LIFE Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 3.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
aTyr Pharma Share Price & Price History
Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 06/4/2024 10:09 PM ET
aTyr Pharma Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/31/2024 | Jill Marie Broadfoot | CFO | Buy | 5,000 | $1.79 | $8,950.00 | 27,960 |  |
| 5/31/2024 | Sanjay Shukla | CEO | Buy | 20,000 | $1.81 | $36,200.00 | 136,548 | |
| 5/30/2024 | Timothy Coughlin | Director | Buy | 50,000 | $1.75 | $87,500.00 | 56,000 | |
| 12/11/2023 | Sanjay Shukla | CEO | Buy | 3,000 | $1.17 | $3,510.00 | 94,173 | |
| 5/10/2023 | Paul Schimmel | Director | Buy | 200,000 | $2.25 | $450,000.00 | 313,023 | |
| 2/6/2023 | Jill Marie Broadfoot | CFO | Sell | 1,566 | $2.36 | $3,695.76 | 15,460 | |
aTyr Pharma Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/10/2024 | Acadian Asset Management LLC | 45,366 | $87K | 0.0% | +119.6% | 0.066% |  |
| 5/10/2024 | Vanguard Group Inc. | 2,652,157 | $5.17M | 0.0% | +12.0% | 3.843% | |
| 5/7/2024 | SG Americas Securities LLC | 28,256 | $55K | 0.0% | N/A | 0.041% | |
| 5/3/2024 | GSA Capital Partners LLP | 224,147 | $0.44M | 0.0% | +105.3% | 0.330% | |
| 4/15/2024 | Kingswood Wealth Advisors LLC | 60,000 | $0.12M | 0.0% | N/A | 0.088% | |
| 2/14/2024 | Pale Fire Capital SE | 293,706 | $0.41M | 0.1% | +425.8% | 0.502% | |
| 2/13/2024 | Stonepine Capital Management LLC | 482,258 | $0.68M | 0.3% | -89.6% | 0.824% | |
| 1/29/2024 | Granite Bay Wealth Management LLC | 18,000 | $25K | 0.0% | N/A | 0.031% | |
| 11/14/2023 | Pale Fire Capital SE | 55,857 | $88K | 0.0% | N/A | 0.095% | |
| 11/13/2023 | Federated Hermes Inc. | 10,169,600 | $16.07M | 0.0% | -0.2% | 17.366% | |
| 11/13/2023 | FMR LLC | 8,556,925 | $13.52M | 0.0% | +5.1% | 14.612% | |
| 8/11/2023 | D.A. Davidson & CO. | 22,750 | $49K | 0.0% | +89.6% | 0.042% | |
| 7/24/2023 | Vontobel Holding Ltd. | 30,000 | $65K | 0.0% | N/A | 0.055% | |
| 5/15/2023 | Stonepine Capital Management LLC | 4,825,722 | $10.13M | 3.4% | N/A | 8.888% | |
| 5/8/2023 | Federated Hermes Inc. | 10,189,966 | $21.40M | 0.1% | +94.8% | 19.168% | |
| 2/15/2023 | Tang Capital Management LLC | 123,430 | $0.27M | 0.0% | -88.9% | 0.425% | |
| 2/14/2023 | VR Adviser LLC | 1,171,436 | $2.57M | 0.4% | -89.1% | 4.038% | |
| 2/9/2023 | Citigroup Inc. | 428,460 | $0.94M | 0.0% | N/A | 1.497% | |
| 11/17/2022 | Telemetry Investments L.L.C. | 492,500 | $1.48M | 1.9% | +10.2% | 1.720% | |
| 11/14/2022 | VR Adviser LLC | 10,698,889 | $36.74M | 5.4% | +664.8% | 37.376% | |
| 7/28/2022 | D.A. Davidson & CO. | 10,800 | $31K | 0.0% | N/A | 0.038% | |
| 5/16/2022 | Tikvah Management LLC | 1,350,833 | $7.23M | 2.3% | +10.2% | 4.860% | |
| 5/16/2022 | Deep Track Capital LP | 1,028,515 | $5.50M | 0.4% | -6.5% | 3.700% | |
| 2/15/2022 | Stonepine Capital Management LLC | 525,531 | $3.93M | 1.8% | +28.0% | 1.891% | |
| 2/14/2022 | Deep Track Capital LP | 1,100,000 | $8.22M | 0.6% | N/A | 3.958% | |
| 2/14/2022 | GSA Capital Partners LLP | 58,791 | $0.44M | 0.1% | N/A | 0.212% | |
| 2/14/2022 | Tikvah Management LLC | 1,225,833 | $9.16M | 2.6% | N/A | 4.411% | |
| 2/10/2022 | Qube Research & Technologies Ltd | 11,665 | $87K | 0.0% | N/A | 0.042% | |
| 2/9/2022 | Dimensional Fund Advisors LP | 226,712 | $1.69M | 0.0% | +1.1% | 0.816% | |
| 2/8/2022 | Raymond James & Associates | 24,584 | $0.18M | 0.0% | N/A | 0.088% | |
| 2/1/2022 | Qube Research & Technologies Ltd | 11,665 | $87K | 0.0% | N/A | 0.042% | |
| 11/16/2021 | Tang Capital Management LLC | 1,113,453 | $10.11M | 2.1% | N/A | 6.581% | |
| 11/16/2021 | Two Sigma Advisers LP | 482,450 | $4.38M | 0.0% | +302.2% | 2.851% | |
| 11/16/2021 | Two Sigma Investments LP | 541,721 | $4.92M | 0.0% | +3,650.0% | 3.202% | |
| 11/16/2021 | Telemetry Investments L.L.C. | 165,318 | $1.50M | 2.0% | -7.8% | 0.977% | |
| 11/16/2021 | VR Adviser LLC | 1,565,000 | $14.21M | 1.8% | N/A | 9.249% | |
| 11/15/2021 | Cubist Systematic Strategies LLC | 51,327 | $0.47M | 0.0% | N/A | 0.303% | |
| 11/15/2021 | Marshall Wace LLP | 43,006 | $0.39M | 0.0% | N/A | 0.254% | |
| 11/15/2021 | Tocqueville Asset Management L.P. | 14,850 | $0.14M | 0.0% | N/A | 0.088% | |
| 11/15/2021 | Dimensional Fund Advisors LP | 224,279 | $2.04M | 0.0% | +1.5% | 1.326% | |
| 11/12/2021 | Renaissance Technologies LLC | 179,655 | $1.63M | 0.0% | +1.9% | 1.062% | |
| 11/12/2021 | Stonepine Capital Management LLC | 410,535 | $3.73M | 1.7% | N/A | 2.426% | |
| 11/12/2021 | Geode Capital Management LLC | 130,282 | $1.18M | 0.0% | +18.7% | 0.770% | |
| 11/12/2021 | EAM Global Investors LLC | 152,792 | $1.39M | 0.3% | N/A | 0.903% | |
| 11/12/2021 | EAM Investors LLC | 259,791 | $2.36M | 0.4% | N/A | 1.535% | |
| 11/9/2021 | BlackRock Inc. | 217,012 | $1.97M | 0.0% | -3.5% | 1.283% | |
| 11/3/2021 | Sheaff Brock Investment Advisors LLC | 11,000 | $100K | 0.0% | N/A | 0.065% | |
| 8/16/2021 | State Street Corp | 55,199 | $0.27M | 0.0% | N/A | 0.338% | |
| 8/13/2021 | Northern Trust Corp | 26,105 | $0.13M | 0.0% | +18.5% | 0.162% | |
Data available starting January 2016
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Read More on aTyr Pharma
Today's Range
Now: N/A
52 Week Range
Now: N/A
Volume
269,400 shs
Average Volume
514,103 shs
Market Capitalization
$131.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.19
Who are the company insiders with the largest holdings of aTyr Pharma?
